Coronavirus (Other than SARS-CoV-2) by Molecular Method
Coronaviruses constitute a group of positive strand RNA viruses which cause respiratory infections in a variety of animal species including humans. In humans, although coronavirus remains at low endemic levels throughout the year, episodic outbreaks occur mostly during the winter and spring months. During epidemics, coronavirus infections constitute up to 35% of all the viral upper respiratory infections and most people will be infected with coronavirus at some point in their lifetime. The pediatric population is particularly vulnerable, although the disease has been reported across all the age groups.
There are five known types of coronaviruses that can infect people. There are two alpha types: 229E and NL63; two beta types: OC43, HKU1; and the type that causes SARS, SARS-CoV. During 2002-2003, a novel coronavirus was discovered and implicated in an outbreak of severe acute respiratory syndrome (SARS) affecting about 8,000 people worldwide. Most coronaviruses infect only one, or at most a few closely related, species including monkeys, dogs, cats and rodents. The SARS coronavirus, however, can infect multiple species. Although the last reported case of SARS-Coronavirus infection was in 2004, it continues to be clinically significant due to its high mortality. The coronaviruses (NL63 and HKU1) were discovered between 2004 and 2005 and implicated in acute respiratory illness. Their clinical impact in terms of morbidity and mortality were comparable to those of 229E and OC43.
In 2012, another novel coronavirus was found to be implicated in an acute severe respiratory illness. First described in Saudi Arabia, the virus was named Middle East Respiratory Syndrome - Coronavirus (MERS-CoV). As of August 20, 2013, 96 cases and 47 deaths due to MERS-CoV have been reported. Cases reported so far are in the Middle Eastern and European countries. No case has been reported in the United States so far.
New type of coronavirus known as SARS-CoV-2 or 2019‐nCoV was identified in city of Wuhan, China, in December 2019, which is causing ongoing outbreak throughout the world effecting many countries and continents.
The genome of 2019‐nCov was sequenced very early during this outbreak indicating that the 2019‐nCoV belongs to the β‐coronavirus genus, with a 79.0% nucleotide identity to SARS‐CoV and 51.8% identity to MERS‐CoV. Sequencing the virus helped scientific community to develop a diagnostic molecular assay for early detection and diagnosis to help prevent spreading of the virus.
The major clinical symptoms of Coronavirus Disease 2019 (COVID-19) caused by 2019‐nCoV infection include fever, dry cough, myalgia, fatigue, and diarrhea. Many patients also developed dyspnea and lymphopenia. Complications of 2019‐nCoV infections included acute respiratory distress syndrome, RNAaemia, acute cardiac injury, and secondary (super‐)infections. Sever lung damage has been shown in many cased most likely caused by sever immune response to the viral infection.
- Diagnosis of Severe Acute Respiratory Syndrome (SARS)
- Diagnosis of Middle-east Respiratory Syndrome (MERS)
- To confirm infecton with coronaviruses 229E, OC43, NL63, HKU1, SARS-CoV and MERS-CoV
- As an aid in diagnosis of acute respiratory distress syndrome and sever pneumonia caused by SARS-CoV-2 coronavirus
- Detection of coronavirus nucleic acids in conjunction with other clinical, radiological and laboratory criteria confirms the diagnosis of acute viral respiratory illness due to coronavirus.
- Positive result for coronavirus by PCR alone (in the absence of clinical symptoms) doesn't imply disease.
- Positive result doesn't rule out co-infections with other respiratory viruses or bacteria.
- Negative result doesn't rule out the possibility of coronavirus infection.
Not detected
Respiratory swabs, nasopharyngeal swab, sputum, endotracheal and endobronchial aspirates are acceptable specimens.
Stability
- Ambient: 1-3 days
- Refrigerated: 7 days
- Int J Occup Environ Med. 2020 Feb 5;11(2):65-71. [PMID: 32020915]
- Lancet Infect Dis. 2020 Mar 23. pii: S1473-3099(20)30196-1. [PMID: 32213337]
- Euro Surveill. 2020 Jan;25(3). doi: 10.2807/1560-7917. [PMID: 31992387]
- Int J Antimicrob Agents. 2020 Feb 17:105924. [PMID: 32081636]
- J Med Virol. 2020 Feb 13. doi: 10.1002/jmv.25709. [PMID: 32056249]
- Pediatr Infect Dis J. 2005 Nov;24 (11 Suppl). [PMID: 16378050]
- Euro Surveill. 2012 Sep 27;17(39). [PMID: 23041020]
- Antivir Ther. 2007;12(4 Pt B):651-8. [PMID: 17944272]